CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer

RegulatorypositiveLifyorliPositive

AI Analysis

Summary

The European CHMP committee recommended approval of Corcept Therapeutics' Lifyorli combination therapy for platinum-resistant ovarian cancer, supporting its path to European authorization.

Outcome Details

CHMP (Committee for Medicinal Products for Human Use) backed Lifyorli combination therapy

Importance:7/10

Sentiment:

0.75

regulatoryCHMPoncologycombination therapyEurope

Related Companies

$CORT

Read the original article

Published by yahoo_finance on September 21, 2026 3:07 PM

Read Original